Assessing the effectiveness of AS-48 in experimental mice models of Chagas' disease.
J Antimicrob Chemother
; 75(6): 1537-1545, 2020 06 01.
Article
en En
| MEDLINE
| ID: mdl-32129856
OBJECTIVES: We report the in vivo trypanocidal activity of the bacteriocin AS-48 (lacking toxicity), which is produced by Enterococcus faecalis, against the flagellated protozoan Trypanosoma cruzi, the aetiological agent of Chagas' disease. METHODS: We determined the in vivo activity of AS-48 against the T. cruzi Arequipa strain in BALB/c mice (in both acute and chronic phases of Chagas' disease). We evaluated the parasitaemia, the reactivation of parasitaemia after immunosuppression and the nested parasites in the chronic phase by PCR in target tissues. RESULTS: AS-48 reduced the parasitaemia profile in acute infection and showed a noteworthy reduction in the parasitic load in chronic infection after immunosuppression according to the results obtained by PCR (double-checking to demonstrate cure). CONCLUSIONS: AS-48 is a promising alternative that provides a step forward in the development of a new therapy against Chagas' disease.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Trypanosoma cruzi
/
Enfermedad de Chagas
Idioma:
En
Revista:
J Antimicrob Chemother
Año:
2020
Tipo del documento:
Article